JOURNAL OF RHEUMATOLOGY, cilt.32, sa.1, ss.98-105, 2005 (SCI-Expanded)
Objective. To determine the effect of the tumor necrosis factor-a blocker-etanercept on the pathergy and monosodium urate (MSU) status and on the mucocutaneous and articular manifestations of patients with Behcet's disease (BD).